Table 1.

Demographic characteristics of ALL survivors and participants in the 2003 BRFSS, 18-44 y old

ALL survivors (N = 2,648), n (%)BRFSS (N = 110,623), n (%)P
Age at interview, y
    18-24788 (29.8)18,359 (16.6)<0.001
    25-341,375 (51.9)40,238 (36.4)
    35-44485 (18.3)52,026 (47.0)
Sex
    Male1,314 (49.6)44,945 (40.6)<0.001
    Female1,334 (50.4)65,678 (59.4)
Race/ethnicity
    White, NH2,332 (88.4)122,803 (72.5)<0.001
    Black, NH81 (3.1)14,582 (9.4)
    Other, NH87 (3.3)11,417 (7.6)
    Hispanic/Latino138 (5.2)14,807 (10.6)
Household income (US$)
    <20,000321 (14.6)17,832 (17.9)<0.001
    ≥20,0001,875 (85.4)81,943 (82.1)
Educational level
    Did not graduate HS120 (4.6)9,639 (8.7)<0.001
    Graduated from HS442 (16.8)31,939 (28.9)
    Some college or technical school1,061 (40.4)32,147 (29.1)
    Graduated from college or technical school1,003 (38.2)36,746 (33.3)
Current smoker
    Yes419 (15.9)28,676 (26.0)<0.001
    No2,219 (84.1)81,773 (74.0)
BMI categories
    Neither overweight nor obese (<25 kg/m2)1,031 (40.6)44,171 (45.7)<0.001
    Overweight (25 to <30 kg/m2)814 (32.1)34,875 (33.1)
    Obese (≥30 kg/m2)694 (27.3)22,450 (21.3)
Cancer therapy
    Chemotherapy (% yes)*
        Cytarabine1,286 (53.0)Not applicable
        Cyclophosphamide1,232 (50.8)
        Daunorubicin697 (28.7)
        Dexamethasone295 (12.2)
        Doxorubicin673 (27.8)
        Thioguanine365 (15.1)
        Etoposide198 (8.2)
    Anthracycline, any
        None1,301 (55.0)Not applicable
        <300 mg/m2662 (28.0)
        ≥300 mg/m2404 (17.0)
    CRT (Gy)
        None810 (35.5)Not applicable
        10.0-19.9695 (30.4)
        ≥20778 (34.1)
  • NOTE: Percentage is based upon available data for each variable.

    Abbreviations: NH, non-Hispanic; HS, high school; CRT, cranial radiation therapy.

  • * Over 90% of survivors received the following chemotherapy agents: l-asparaginase, 6-mercaptopurine, methotrexate, prednisone, and vincristine.